NASDAQ:TGTX
TG Therapeutics (TGTX)
TG Therapeutics (TGTX) is covered by Stockchase stock experts. Read their latest opinions, ratings and top picks below.
Financials 
Technical Analysis 
Developing drugs for MS and blood cancers like leukemia. Exciting prospects; boasts promising clinical trial results, especially for their MS drug. Last month, they announced good phase 3 results for that drug which lifted share from the $30's to $50's. Cash flow is fine; they just said they've raised a lot of money.
- «
- ‹
- 1
- ›
- »
Popular Articles
TG Therapeutics (TGTX) Frequently Asked Questions
What is TG Therapeutics stock symbol?
TG Therapeutics is a American stock, trading under the symbol TGTX (previously TGTX-Q on Stockchase) on the NASDAQ (TGTX). It is usually referred to as NASDAQ:TGTX or TGTX
Is TG Therapeutics a buy or a sell?
In the last year, 1 stock analyst issued a Buy, Sell, or Hold rating on TGTX (previously TGTX-Q on Stockchase). 1 analyst recommended to BUY and 0 analysts recommended to SELL the stock. The latest stock analyst rating is TOP PICK. Read the latest stock experts' ratings for TG Therapeutics.
Is TG Therapeutics a good investment or a top pick?
TG Therapeutics was recommended as a Top Pick by The Panic-Proof Portfolio (Stockchase Research) on 2026-10-22. Read the latest stock experts ratings for TG Therapeutics.
Why is TG Therapeutics stock dropping?
Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for TG Therapeutics.
Is TG Therapeutics worth watching?
TG Therapeutics is followed by 10 investors on Stockchase and is a trending stock that is worth watching.
What is TG Therapeutics stock price?
On 2026-11-03, TG Therapeutics (TGTX) stock closed at a price of $61.04.
The developer of a medication for relapsing MS in patients has seen an 88% reduction in progression after seven years of usage. It trades at 13x earnings and supports a 100% ROE. We like that quarterly cash reserves are growing along with cash flow. We recommend setting a stop-loss at $41, looking to achieve $70 -- upside potential of 30%. Yield 0%
(Analysts’ price target is $69.70)